Clinical trials: Stage IV Melanoma
BRAF V600 Mutated-Stage III/IV Melanoma
Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma
This was a retrospective chart review study of all proto-oncogene B-Raf (BRAF) V600-mutated patients who received adjuvant checkpoint inhibitor (CPI) therapy, relapsed locoregionally or distantly, and were again resected to no…
- Trial name
- NCT06557291
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Novartis
Melanoma (Skin)
SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma
RATIONALE: Surgery may be effective therapy in treating patients with metastatic melanoma. PURPOSE: This phase II trial is studying how well surgery works in treating patients with metastatic melanoma.
- Trial name
- NCT00002860
- Testing
- Surgery
- Where
- 124 sites in United States
- Volunteers
- 77 people
- Sponsor
- SWOG Cancer Research Network
Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
A single-center, open-label, non-randomized phase I/II study to evaluate the efficacy, safety and tolerance of crizanlizumab monotherapy and in combination with nivolumab in patients with advanced glioblastoma (GB) who exhausted…
- Conditions
- Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System, MGMT-Unmethylated Glioblastoma
- Trial name
- 14 (NCT05909618)
- Testing
- Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO], Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
- Where
- Israel
- Volunteers
- 33 people
- Sponsor
- Sheba Medical Center
Melanoma
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.
- Trial name
- NCT02714218
- Testing
- Nivolumab 3 mg/kg IV, Ipilimumab 1 mg/kg IV, Nivolumab 1 mg/kg IV
- Where
- 57 sites in United States, Australia and 11 more
- Volunteers
- 387 people
- Sponsor
- Bristol-Myers Squibb
Cancer, Melanoma
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
This is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the tolerability of Sorafenib in combination with…
- Trial name
- NCT00110994
- Testing
- Sorafenib (Nexavar, BAY43-9006), Dacarbazine
- Where
- 14 sites in United States
- Volunteers
- 101 people
- Sponsor
- Bayer
Stage IV Melanoma
Investigating Participation Patterns Among Stage IV Melanoma Patients
Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the safety and efficacy of new treatments for this disease.
- Trial name
- NCT06093594
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Metastatic Melanoma
Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
This is an open-label, dose finding, multiple-dose study in subjects with metastatic melanoma. Three dose levels of MPC-6827 will be administered with temozolomide to three separate cohorts.
- Trial name
- NCT00609011
- Testing
- MPC-6827 + Temozolomide
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Myrexis Inc.
Patients With Intransit Stage III/IV Melanoma
Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma
In this study the recombinant human fusion protein L19TNFα will be associated in ILP with the standard treatment with melphalan 10mg/l limb volume in subjects affected by stage III/IV limb melanoma.
- Trial name
- NCT01213732
- Testing
- Isolated inferior limb perfusion
- Where
- 2 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Philogen S.p.A.
Metastatic Melanoma
Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study
This study evaluates the safety as well as the potential clinical efficacy of an adoptive transfer of CD8+ T cells, sorted with HLA-peptide multimers and specific for Melan-A and MELOE-1 melanoma antigens, to patients suffering…
- Trial name
- MelSort (NCT02424916)
- Testing
- Melanoma antigens-specific CD8+ T lymphocytes
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Nantes University Hospital
Solid Tumors, Metastatic Melanoma
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04140500
- Testing
- RO7247669
- Where
- 25 sites in Denmark, Georgia and 7 more
- Volunteers
- 170 people
- Sponsor
- Hoffmann-La Roche
Melanoma Stage IV
Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis
Malignant melanoma, is a kind of malignant tumor derived from melanocytes. It is common in skin, mucous membrane, eye choroid and other parts.
- Trial name
- NCT05070221
- Testing
- Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF), Recombinant humanized anti-PD-1 monoclonal antibody for injection, Axitinib
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma (Skin)
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells.Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00002767
- Testing
- Detox-B adjuvant, recombinant interferon alfa
- Where
- 27 sites in United States
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Stage III Melanoma, Stage IV Melanoma
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
This is a Phase II single-arm, open-label, clinical trial evaluating the efficacy and safety of pazopanib in combination with paclitaxel as first line therapy for subjects with unresectable Stage III and Stage IV melanoma.
- Conditions
- Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma
- Trial name
- NCT01107665
- Testing
- Pazopanib and Paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Irvine
Stage IIIB Melanoma, Stage IIIC Melanoma
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
This pilot phase II trial is studying how well RO4929097 works in treating patients with stage III, or stage IV melanoma that can be removed by surgery.
- Conditions
- Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Trial name
- NCT01216787
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, pharmacological study, therapeutic conventional surgery
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or…
- Trial name
- coBRIM (NCT01689519)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 495 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma
A Novel Treatment for Metastatic Melanoma
A novel treatment for metastatic melanoma combining a laser and an immune-system stimulating cream.
- Trial name
- NCT00758797
- Testing
- Photoimmunotherapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Northwestern University
Melanoma
Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom
The purpose of this study is to describe the first-line therapy landscape for patients with advanced melanoma and to describe clinical outcomes and healthcare resource utilization in a subset of treatment-naïve patients who…
- Trial name
- NCT03448497
- Testing
- Non-interventional
- Where
- United Kingdom
- Volunteers
- 333 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Melanoma, Stage IV Melanoma
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
This phase II trial is studying how well giving carboplatin and paclitaxel together with bevacizumab works in treating patients with stage IV melanoma that cannot be removed by surgery.
- Trial name
- NCT00255762
- Testing
- carboplatin, paclitaxel, bevacizumab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of two dose levels of RO7247669 in participants with unresectable or metastatic melanoma to select the recommended dose for…
- Trial name
- NCT05419388
- Testing
- RO7247669
- Where
- 22 sites in Australia, Brazil and 8 more
- Volunteers
- 93 people
- Sponsor
- Hoffmann-La Roche
Metastatic Melanoma, Skin Cancer
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Background: Some cancer treatments collect a patient s own blood cells to use as specialized cancer-fighting cells. Collected white blood cells known as PBL (peripheral blood lymphocytes) can use to isolate special cells that can…
- Trial name
- NCT01495572
- Testing
- Fludarabine, Cyclophosphamide, Aldesleukin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.